iBio, Inc. Prices $16,000,000 Public Offering
June 22, 2018 07:26 ET
|
iBio, Inc.
NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” OR THE “COMPANY”), today announced the pricing of an underwritten public offering with expected total gross...
iBio, Inc. Announces Completion of 1-For-10 Reverse Stock Split
June 08, 2018 16:30 ET
|
iBio, Inc.
NEW YORK, June 08, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that its previously announced 1-for-10 reverse stock split of common stock...
iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
June 08, 2018 16:01 ET
|
iBio, Inc.
NEW YORK, June 08, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that on June 6, 2018, the Company received a letter from NYSE American LLC...
iBio and ONEWAY Diagnostica Develop New Products for Brazil
June 05, 2018 08:30 ET
|
iBio, Inc.
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced a joint product development, manufacturing and revenue sharing agreement with ONEWAY Diagnostica of Brazil...
iBio, Inc. Announces Reverse Stock Split
May 31, 2018 08:30 ET
|
iBio, Inc.
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today a reverse split of its Common Stock, par value $0.001 per share (the “Common...
iBio Selects Lead Candidate for its Fibrosis Therapeutics Program
March 14, 2018 08:30 ET
|
iBio, Inc.
NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio”) announced today that it had selected an E4-Fc fusion protein as its lead candidate for further development of a...
iBio Patent Issues in China on Protein Glycosylation Modification
March 12, 2018 08:30 ET
|
iBio, Inc.
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“iBio”) announced the expansion of its intellectual property portfolio with the issuance of a patent in China describing...
iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics
March 07, 2018 08:45 ET
|
iBio, Inc.
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“iBio”) announced the expansion of its CDMO capabilities and services to include the development and cGMP manufacturing...
iBio, Inc. Provides Corporate Update
January 05, 2018 17:00 ET
|
iBio, Inc.
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today its receipt of notice that Staff of NYSE American LLC determined that the...
iBio, Inc. Closes $4,500,000 Offering of Common Stock
November 30, 2017 16:15 ET
|
iBio, Inc.
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”), today announced the closing of its previously announced public offering of 22,500,000 shares of...